Added to YB: 2025-04-16
Pitch date: 2025-04-14
NVO [bullish]
Novo Nordisk A/S
-25.6%
current return
Author Info
FluentInQuality invests in high-quality businesses that generate steady and sustainable cashflows, proven track records, and the potential to act as a true compounding machines over the long run. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.4T
Pitch Price
DKK 65.12
Price Target
N/A
Dividend
3.76%
EV/EBITDA
9.60
P/E
13.52
EV/Sales
4.81
Sector
Pharmaceuticals
Category
value
3 Undervalued High-Quality Stocks You Can Not Afford To Miss - Novo Nordisk A/S
NVO: Dominates global diabetes/obesity markets (30%+ insulin share, leading GLP-1 drugs Ozempic/Wegovy). Expanding into cardiovascular, kidney, Alzheimer's, addiction treatments. Strong financials: 40%+ operating margins, 60-70% ROIC, minimal debt. Resilient model with recurring revenue, global presence. TAM growing with 1B+ obese patients worldwide.
Read full article (2 min)